|
1
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lussier DM, O'Neill L, Nieves LM, McAfee
MS, Holechek SA, Collins AW, Dickman P, Jacobsen J, Hingorani P and
Blattman JN: Enhanced T-cell immunity to osteosarcoma through
antibody blockade of PD-1/PD-L1 interactions. J Immunother.
38:96–106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zheng S, Jiang F, Ge D, Tang J, Chen H,
Yang J, Yao Y, Yan J, Qiu J, Yin Z, et al: LncRNA
SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of
osteosarcoma. Biomed Pharmacother. 112:1086952019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Awasthi R, Rathbone MJ, Hansbro PM, Bebawy
M and Dua K: Therapeutic prospects of microRNAs in cancer treatment
through nanotechnology. Drug Deliv Transl Res. 8:97–110. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petri BJ and Klinge CM: Regulation of
breast cancer metastasis signaling by miRNAs. Cancer Metastasis
Rev. 39:837–886. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang N, Ekanem NR, Sakyi CA and Ray SD:
Hepatocellular carcinoma and microRNA: New perspectives on
therapeutics and diagnostics. Adv Drug Deliv Rev. 81:62–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Konoshenko MY, Bryzgunova OE and Laktionov
PP: miRNAs and radiotherapy response in prostate cancer. Andrology.
9:529–545. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Y, Huang Y, Lin W, Liu J, Chen X,
Chen C, Yu X and Teng L: Host miRNAs-microbiota interactions in
gastric cancer. J Transl Med. 20:522022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hermansen SK and Kristensen BW: MicroRNA
biomarkers in glioblastoma. J Neurooncol. 114:13–23. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ali Syeda Z, Langden SSS, Munkhzul C, Lee
M and Song SJ: Regulatory mechanism of microRNA expression in
cancer. Int J Mol Sci. 21:17232020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fridrichova I and Zmetakova I: MicroRNAs
contribute to breast cancer invasiveness. Cells. 8:13612019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi
S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers,
therapies, and resistance in cancer. Int J Biol Sci. 16:2628–2647.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xin X, Kumar V, Lin F, Kumar V, Bhattarai
R, Bhatt VR, Tan C and Mahato RI: Redox-responsive nanoplatform for
codelivery of miR-519c and gemcitabine for pancreatic cancer
therapy. Sci Adv. 6:eabd67642020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren D, Yang Q, Dai Y, Guo W, Du H, Song L
and Peng X: Oncogenic miR-210-3p promotes prostate cancer cell EMT
and bone metastasis via NF-κB signaling pathway. Mol Cancer.
16:1172017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang L, Chen HY, Hao NB, Tang B, Guo H,
Yong X, Dong H and Yang SM: microRNA inhibitors: Natural and
artificial sequestration of microRNA. Cancer Lett. 407:139–147.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qi X, Zhang DH, Wu N, Xiao JH, Wang X and
Ma W: ceRNA in cancer: Possible functions and clinical
implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang G, Liang M, Liu H, Huang J, Li P,
Wang C, Zhang Y, Lin Y and Jiang X: CircRNA hsa_circRNA_104348
promotes hepatocellular carcinoma progression through modulating
miR-187-3p/RTKN2 axis and activating Wnt/β-catenin pathway. Cell
Death Dis. 11:10652020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao M, Feng J and Tang L: Competing
endogenous RNAs in lung cancer. Cancer Biol Med. 18:1–20. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ye J, Li J and Zhao P: Roles of ncRNAs as
ceRNAs in gastric cancer. Genes (Basel). 12:10362021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He Y, Zhou H, Wang W, Xu H and Cheng H:
Construction of a circRNA-miRNA-mRNA regulatory network reveals
potential mechanism and treatment options for osteosarcoma. Front
Genet. 12:6323592021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hill KE, Kelly AD, Kuijjer ML, Barry W,
Rattani A, Garbutt CC, Kissick H, Janeway K, Perez-Atayde A,
Goldsmith J, et al: An imprinted non-coding genomic cluster at
14q32 defines clinically relevant molecular subtypes in
osteosarcoma across multiple independent datasets. J Hematol Oncol.
10:1072017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pan Y, Lu L, Chen J, Zhong Y and Dai Z:
Identification of potential crucial genes and construction of
microRNA-mRNA negative regulatory networks in osteosarcoma.
Hereditas. 155:212018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang J, Wu Z, Zheng M, Yu S, Zhang X and
Xu X: CD146 is closely associated with the prognosis and molecular
features of osteosarcoma: Guidance for personalized clinical
treatment. Front Genet. 13:10253062022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han D, Wang M, Yu Z, Yin L, Liu C, Wang J,
Liu Y, Jiang S, Ren Z and Yin J: FGF5 promotes osteosarcoma cells
proliferation via activating MAPK signaling pathway. Cancer Manag
Res. 11:6457–6466. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Diboun I, Wernisch L, Orengo CA and
Koltzenburg M: Microarray analysis after RNA amplification can
detect pronounced differences in gene expression using limma. BMC
Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Varet H, Brillet-Guéguen L, Coppee JY and
Dillies MA: SARTools: A DESeq2- and EdgeR-Based R pipeline for
comprehensive differential analysis of RNA-Seq data. PLoS One.
11:e01570222016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36:D149–D153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen C, Xie L, Ren T, Huang Y, Xu J and
Guo W: Immunotherapy for osteosarcoma: Fundamental mechanism,
rationale, and recent breakthroughs. Cancer Lett. 500:1–10. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li X, Ding J, Wang X, Cheng Z and Zhu Q:
NUDT21 regulates circRNA cyclization and ceRNA crosstalk in
hepatocellular carcinoma. Oncogene. 39:891–904. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu N, Yang W, Liu Y, Yan F and Yu Z:
MicroRNA-411 promoted the osteosarcoma progression by suppressing
MTSS1 expression. Environ Sci Pollut Res Int. 25:12064–12071. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chan JJ and Tay Y: Noncoding RNA: RNA
regulatory networks in cancer. Int J Mol Sci. 19:13102018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Misir S, Hepokur C, Aliyazicioglu Y and
Enguita FJ: Circular RNAs serve as miRNA sponges in breast cancer.
Breast Cancer. 27:1048–1057. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He M, Wang G, Jiang L, Qiu C, Li B, Wang J
and Fu Y: miR-486 suppresses the development of osteosarcoma by
regulating PKC-δ pathway. Int J Oncol. 50:1590–1600. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu Y, Zhang J, Xing C, Wei S, Guo N and
Wang Y: miR-486 inhibited osteosarcoma cells invasion and
epithelial-mesenchymal transition by targeting PIM1. Cancer
Biomark. 23:269–277. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Namløs HM, Skårn M, Ahmed D, Grad I,
Andresen K, Kresse SH, Munthe E, Serra M, Scotlandi K,
Llombart-Bosch A, et al: miR-486-5p expression is regulated by DNA
methylation in osteosarcoma. BMC Genomics. 23:1422022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu J, Xia L, Yao X, Yu X, Tumas KC, Sun W,
Cheng Y, He X, Peng YC, Singh BK, et al: The E3 ubiquitin ligase
MARCH1 regulates antimalaria immunity through interferon signaling
and T cell activation. Proc Natl Acad Sci USA. 117:16567–16578.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meng Y, Hu J, Chen Y, Yu T and Hu L:
Silencing MARCH1 suppresses proliferation, migration and invasion
of ovarian cancer SKOV3 cells via downregulation of NF-κB and
Wnt/β-catenin pathways. Oncol Rep. 36:2463–2470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang W, Su J, Li M, Li T, Wang X, Zhao M
and Hu X: Myricetin induces autophagy and cell cycle arrest of HCC
by inhibiting MARCH1-regulated Stat3 and p38 MAPK signaling
pathways. Front Pharmacol. 12:7095262021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang N, Yang L, Dai J, Wu Y, Zhang R, Jia
X and Liu C: 5-FU inhibits migration and invasion of CRC cells
through PI3K/AKT pathway regulated by MARCH1. Cell Biol Int.
45:368–381. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Su Y, Feng W, Zhong G, Ya Y, Du Z, Shi J,
Chen L, Dong W and Lin T: ciRs-6 upregulates March1 to suppress
bladder cancer growth by sponging miR-653. Aging (Albany NY).
11:11202–11223. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y,
Yoon T, Azzam DJ, Twyman-Saint Victor C, Wiemann BZ, Ishwaran H, et
al: Exosome transfer from stromal to breast cancer cells regulates
therapy resistance pathways. Cell. 159:499–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
